It was reported on Thursday that United States-based BioMarin has named Maykin Ho, PhD, as its new director.
Dr Ho has over 30 years of experience in the healthcare and finance industries. She is serving on the boards of Agios Pharmaceuticals Inc, FibroGen Inc, Grail Inc, Parexel, the Aaron Diamond AIDS Research Center, and the Institute for Protein Innovation. She is a venture partner of Qiming Venture Partners and a member of the Biotech Advisory Panel of the Stock Exchange of Hong Kong. She has served in Goldman Sachs Group, DuPont-Merck Pharmaceuticals and DuPont de Nemours & Company.
Jean-Jacques Bienaime, chairman and CEO at BioMarin, said, 'We are thrilled to welcome Maykin to BioMarin's board of directors. She brings a breadth and depth of experience in the healthcare industry and finance to an already exceptional board. Maykin brings an important perspective to support BioMarin's growth trajectory as we strive to address the unmet medical needs of people affected by rare genetic diseases and deliver scientific breakthroughs.'
Kromek collaborates on next-gen CT detector technology
Gilead Sciences initiates Phase 2 trial in Europe to evaluate lenacapavir for HIV prevention
European Commission grants authorisation to ViiV Healthcare's Apretude for prevention of HIV
Celanese to supply VitalDose drug delivery platform for Population Council's MPT Intravaginal Ring
Henry Schein introduces equipment repair subscription - Henry Schein Thrive Service Plus
Seres Therapeutics provides business updates and reports Q2 2023 financial results